Artificial Urinary Sphincter Market Size & Growth Forecast 2027–2036, By Segments (Brand, End-user), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Artificial Urinary Sphincter Market size was assessed at USD 643.4 million in 2026 and is poised to grow at a 6.75% CAGR between 2027 and 2036, exceeding USD 1.24 billion by 2036. The industry revenue for 2027 is estimated at USD 679.95 million.

• Base Year Value (2026): USD 643.4 million
• CAGR (2027-2036): 6.75%
• Forecast Year Value (2036): USD 1.24 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Artificial Urinary Sphincter Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds largest share due to established urology pathways, experienced surgeons, and advanced hospital infrastructure enabling routine artificial urinary sphincter implantation for incontinence management.
  • Asia Pacific is growing at 8.14% CAGR driven by improved access to urology services, expanding specialist availability, and gradual shift toward surgical continence treatments in urban hospitals.

• Segment Momentum:

  • AMS 800 held an 80.99% market share in 2026, supported by strong clinical familiarity, long-term integration into treatment pathways, and physician confidence in its reliability and established surgical use.
  • The female segment is growing fastest as clinicians increasingly evaluate artificial urinary sphincters for complex incontinence cases where conventional treatment options may not provide adequate long-term management.

• Market Expansion Drivers:

  • Rising prevalence of prostate cancer, BPH, and spinal cord injuries driving demand.
  • Expanding insurance reimbursement coverage supporting wider hospital adoption of AUS procedures.
  • Adoption of smart automated sphincter devices improving post-surgical urinary incontinence management.

• Leading Market Participants:

  Key companies in the artificial urinary sphincter market include Boston Scientific Corporation (United States), Coloplast A/S (Denmark), Zephyr Surgical Implants (Switzerland), GT Urological (United States), UroMems SAS (France), Rigicon, Inc. (United States), Affluent Medical SA (France).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 643.4 million
  • 2027 Estimated Market Size: USD 679.95 million.
  • Projected Market Size: USD 1.24 billion by 2036
  • Growth Forecasts: 6.75% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: AMS 800 (Brand) | Male (End-user)
  • Emerging Opportunity Segment: AMS 800 (Brand) | Female (End-user)

Market Growth Drivers and Industry Trends

Rising prevalence of prostate cancer, BPH, and spinal cord injuries driving demand

The increasing incidence of conditions associated with urinary sphincter dysfunction is creating a larger patient pool requiring effective continence management solutions. The artificial urinary sphincter market is supported by demand from patients experiencing stress urinary incontinence following prostate-related conditions, as well as those affected by benign prostatic hyperplasia, spinal cord injuries, and associated urological complications. As urinary control can significantly influence mobility, independence, and quality of life, patients and clinicians are increasingly considering implantable sphincter systems when conservative treatment options provide insufficient symptom control.

Expanding insurance reimbursement coverage supporting wider hospital adoption of AUS procedures

Improved reimbursement availability can reduce the financial barriers associated with artificial urinary sphincter implantation, supporting greater access to specialized urological procedures. Within the artificial urinary sphincter market, broader insurance coverage can encourage hospitals and physicians to offer AUS procedures to eligible patients by improving the affordability and financial feasibility of treatment. Reimbursement support also allows healthcare providers to incorporate advanced continence management into established urological care pathways, particularly where patients require long-term solutions for persistent stress urinary incontinence.

Adoption of smart automated sphincter devices improving post-surgical urinary incontinence management

Technological development in implantable continence devices is creating opportunities for more responsive and patient-oriented approaches to urinary incontinence management. The artificial urinary sphincter market can benefit from smart automated systems designed to improve control, usability, and monitoring following implantation. Greater automation may reduce the need for complex manual intervention while enabling device functionality to respond more effectively to patient requirements, supporting rehabilitation and day-to-day management for individuals experiencing persistent urinary incontinence after surgery or other underlying conditions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of prostate cancer, BPH, and spinal cord injuries driving demand	2.20%	High	North America, Europe	High	Near Term
Expanding insurance reimbursement coverage supporting wider hospital adoption of AUS procedures	1.80%	High	North America, Europe	High	Mid Term
Adoption of smart automated sphincter devices improving post-surgical urinary incontinence management	1.60%	High	North America, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

The artificial urinary sphincter market was led by North America, which held the largest share in 2026. The region benefits from advanced urological care infrastructure, broad access to specialized surgical expertise, and established treatment pathways for male urinary incontinence. Increasing awareness of surgical management options, particularly for patients experiencing persistent incontinence following prostate-related procedures, supports demand for artificial urinary sphincter systems. Continued improvements in implant design, surgical techniques, and postoperative management are also strengthening clinical acceptance. In addition, favorable access to specialized healthcare services and established reimbursement mechanisms support the adoption of advanced continence-restoration procedures.

Asia Pacific is the fastest-growing region, supported by expanding urological healthcare infrastructure, rising healthcare expenditure, and improving access to specialized surgical procedures. Greater awareness of urinary incontinence and its treatment options is encouraging patients to seek definitive interventions rather than relying solely on conservative management. The increasing availability of trained urologists and modern hospital facilities is also improving access to implant-based therapies. Furthermore, the growing prevalence of prostate-related conditions, along with gradual improvements in healthcare coverage and medical technology adoption, is creating a stronger environment for the use of artificial urinary sphincters across the region.

Key Country Insights

United States

Advanced Urology Adoption

The U.S. market emphasizes wider adoption of artificial urinary sphincters through specialized urology centers and continual product refinement. Growing attention to post-prostatectomy incontinence management encourages demand for durable devices supported by clinician training and patient awareness initiatives.

Japan

Precision Surgical Care

Japan focuses on minimally invasive implantation techniques and dependable device performance for patients with urinary incontinence. Japanese hospitals increasingly integrate advanced urological technologies that improve procedural consistency while supporting long-term patient management.

South Korea

Innovation-Driven Procedures

South Korea promotes advanced urological interventions through modern surgical facilities and expanding specialist expertise. The country supports adoption of artificial urinary sphincters that complement precision treatment approaches and enhanced postoperative follow-up.

Germany

Clinical Quality Focus

Germany prioritizes clinically validated artificial urinary sphincter solutions that align with established surgical pathways and hospital quality standards. German healthcare providers favor devices supported by long-term performance data and reliable postoperative patient outcomes.

France

Specialist Care Integration

France emphasizes coordinated urology care with careful patient selection and standardized surgical practices for artificial urinary sphincters. French healthcare providers prioritize technologies that fit established treatment pathways and improve quality-of-life outcomes.

Italy

Reconstructive Urology Support

Italy encourages the use of artificial urinary sphincters within reconstructive urology programs addressing complex urinary incontinence cases. Italian hospitals focus on dependable implant performance and surgeon experience to optimize long-term patient satisfaction.

Segment Leadership and Growth Trends

 

Brand Segment Analysis: AMS 800 (Largest & Fastest-Growing Segment)

The AMS 800 segment dominated the artificial urinary sphincter market, accounting for an 80.99% share in 2026, while also representing the fastest-growing brand segment. Its leading position reflects established clinical familiarity and broad recognition of the device within artificial urinary sphincter procedures. The segment benefits from accumulated physician experience, established surgical techniques, and familiarity with device operation and management among healthcare professionals. In addition, the continued need for effective management of severe urinary incontinence is supporting demand for established artificial urinary sphincter solutions. The combination of clinical familiarity, procedural experience, and continued demand for reliable continence restoration is helping sustain the segment's strong market position.

End-user Segment Analysis: Male (Largest Segment) vs Female (Fastest-Growing Segment)

In the artificial urinary sphincter market, the male segment held the largest position with an 83.18% share in 2026, reflecting the established use of artificial urinary sphincters for managing severe male urinary incontinence. Demand is supported by the occurrence of sphincter-related dysfunction following certain urological procedures and conditions, alongside continued physician familiarity with artificial urinary sphincter implantation in male patients. The established surgical pathway and long-standing clinical use of these devices contribute to the segment's dominant position.

The female segment is the fastest-growing end-user category as clinical interest in artificial urinary sphincter applications for women continues to expand. Increasing recognition of treatment options for severe female urinary incontinence, together with greater attention to individualized continence management, is creating opportunities for broader adoption. Advances in surgical approaches and growing clinical experience with female patients may further support utilization, particularly when conventional treatment options do not provide adequate outcomes. This expanding clinical consideration is strengthening the growth potential of the female segment.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Brand	AMS 800, Others	AMS 800	AMS 800
End-user	Male, Female	Male	Female

Competitive Landscape and Market Positioning

Key companies in the artificial urinary sphincter market:

1. Boston Scientific Corporation (United States)

2. Coloplast A/S (Denmark)

3. Zephyr Surgical Implants (Switzerland)

4. GT Urological (United States)

5. UroMems SAS (France)

6. Rigicon Inc. (United States)

7. Affluent Medical SA (France)

The artificial urinary sphincter market is witnessing steady innovation as companies prioritize advanced implant technologies designed to improve comfort, reliability, and treatment outcomes. Increased investment in device miniaturization, durability enhancement, and surgical efficiency is strengthening product competitiveness within the market. Additionally, the growing need for effective urinary incontinence management solutions is encouraging the expansion of specialized treatment options and next-generation therapeutic systems.

Industry Development/News

Company Name	Date	Key Development
UroMems	May-26	UroMems secured US$60 million in strategic funding from Ajax Health Fund I. This investment is earmarked to support pivotal clinical trials for the UroActive System in the United States and France, while accelerating commercialization preparations for the smart automated artificial urinary sphincter technology designed to treat stress urinary incontinence.
Amber Therapeutics	Mar-24	Amber Therapeutics announced positive results from its first-in-human study of the Amber-UI, an implantable bioelectrical therapy device for urinary incontinence. The clinical data demonstrated favorable safety and performance profiles, establishing the platform as a significant technological development and a potential alternative treatment modality within the broader urinary incontinence clinical landscape.
AIIMS Bhubaneswar	Apr-24	AIIMS Bhubaneswar expanded its urological care infrastructure by introducing specialized artificial urinary sphincter implantation services. This operational expansion increases access to clinical treatments for patients suffering from severe incontinence resulting from prostate surgeries, spinal cord injuries, and related pathologies, enhancing the institution's capacity to deliver advanced restorative care.
UroMems	Nov-24	UroMems appointed a former Axonics executive to its Board of Directors, strategically strengthening its leadership team with deep commercialization and operational expertise. This governance change aligns with the company's objective to transition its UroActive System, an automated artificial urinary sphincter, from clinical development toward large-scale market entry and commercial deployment.